Trastuzumab NCT07407920 Clinical Landscape 2026

Explore the PatSnap Life Sciences MCP marketplace

This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.

Data snapshot: 18 September 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.

Phase 2

Clinical phase

Recruiting

Recruitment status

120

Planned enrollment

2026-09-30

Primary-completion proxy

Executive view

NCT07407920 evaluates Trastuzumab in Residual Neoplasm. The disclosed sponsor is The University of Texas MD Anderson Cancer Center, the design is Interventional, and the geographic footprint is United States. The first listed primary endpoint is Event free survival (EFS), assessed over From breast surgery to evidence of clinical locoregional or distant recurrence of breast cancer or death from breast cancer, up to 3 years.

The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.

PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.

How the MCP evidence stack was assembled

Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT07407920 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Residual Neoplasm landscape. Drug & Asset MCP drug_fetch was queried for Trastuzumab, while Company & Deal Intelligence MCP organization_fetch was queried for The University of Texas MD Anderson Cancer Center.

This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.

Trial landscape table

Trial	Asset / intervention	Phase / status	Sponsor	Geography	Primary endpoint	Readout proxy
NCT07407920	Trastuzumab	Phase 2 / Recruiting	The University of Texas MD Anderson Cancer Center	United States	Event free survival (EFS) From breast surgery to evidence of clinical locoregional or distant r…	2026-09-30
NCT07423117	ITC-6146RO	Phase 1 / Not yet recruiting	IntoCell, Inc.	Geography not reported	Phase 1a (Dose Escalation) Incidence of Adverse Events (AEs) Through study completion (Up to 2 years)	2027-06-30
NCT07419880	Penpulimab	Phase 2 / Not yet recruiting	Fudan University	China	Objective Response Rate (ORR) From date of randomization until the date of first documented progres…	2027-01-30
NCT07413601	Carboplatin	Phase 2 / Not yet recruiting	Cancer Hospital Chinese Academy of Medical Sciences	China	Median Progression-Free Survival (PFS) From date of randomization until the date of first documented progres…	2029-02-10
NCT07408089	Fulvestrant	Phase 1 / Terminated	Boundless Bio, Inc.	United States	Rate of dose limiting toxicities (DLTs) in each BBI-940 monotherapy dose escalation cohort. First 28 days of study treatment (through end of Cycle 1).	2026-07-28

The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.

Reproduce the trial-to-asset workflow with PatSnap MCP

Protocol design and endpoint interpretation

NCT07407920 is a Phase 2, recruiting study with 120 planned participants. Allocation is Non-Randomized, masking is None (Open Label), and the intervention model is Parallel Assignment.

The primary endpoint is “Event free survival (EFS)” over “From breast surgery to evidence of clinical locoregional or distant recurrence of breast cancer or death from breast cancer, up to 3 years.” The retrieved endpoint description is: Will be independently estimated for each cohort, along with corresponding 95% confidence intervals using Kaplan-Meier method..

Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of 120 should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.

No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.

Indexed readouts in the surrounding landscape

5 recent result records were selected as contextual evidence for Residual Neoplasm. These records do not establish direct evidence for NCT07407920 unless the registration number matches.

A Phase I/Ib Trial of the CDK4/6 Antagonist Ribociclib And The HDAC Inhibitor Belinostat In Patients With Metastatic Triple Negative Breast Cancer And Recurrent Ovarian Cancer Wit…

Phase 1; n=12; Rate of Dose Limiting Toxicity (DLT) = 1 Participants ; Rate of Dose Limiting Toxicity (DLT) = 2 Participants Source: https://clinicaltrials.gov/ct2/show/results/NCT04315233

Phase I/IIa Clinical Trial Evaluating the Safety and Efficacy of Rintatolimod Combined With IFNα2b (Bioferon®) to Enhance the Effectiveness of Pembrolizumab in Patients With Metas…

Phase 1/2; n=5; Incidence of Dose Limiting Toxicities = 0 Participants ; Incidence of Dose Limiting Toxicities = 1 Participants Source: https://clinicaltrials.gov/ct2/show/results/NCT05756166

A Phase Ib/II Open Label, Multi-arm, Parallel Cohort Dose Finding and Expansion Study to Assess the Safety, Pharmacokinetics and Efficacy of NUC-3373, a Nucleotide Analogue, Given…

Phase 1/2; n=19; Number of Participants With DLTs in Each Module = 0 Participants ; Number of Participants With DLTs in Each Module = 0 Participants Source: https://clinicaltrials.gov/ct2/show/results/NCT05714553

Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.

Asset and sponsor context

Trastuzumab is indexed as Monoclonal antibody with HER2 biology and a global stage of Approved. The asset profile lists Genentech, Inc. as an originator or developer.

The University of Texas MD Anderson Cancer Center is indexed in United States with the website https://www.mdanderson.org. MD Anderson Cancer Center is a cancer treatment and research institution which gives treatment, and research of all types of cancer. The record lists 219 development-stage drug assets.

For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.

Development white space

Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
Sequencing white space. Clarify whether Trastuzumab is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.

White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.

Strategic implications and next readouts

For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.

For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.

Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.

Source trail and bottom line

Anchor trial: NCT07407920
Protocol source: https://clinicaltrials.gov/study/NCT07407920
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 18 September 2026.

Trastuzumab in Residual Neoplasm is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes Event free survival (EFS) and 2026-09-30 the leading decision points.

Build and refresh clinical landscape reports with PatSnap MCP